Creatine Links Metabolism to Dendritic-Cell Activation in Cancer: A Low-Cost Bridge Mainstream Immunotherapy Coverage Missed

UCLA researchers report that creatine transporter expression rises sharply in tumor-infiltrating dendritic cells, enabling sustained ATP production and inflammatory signaling that primes CD8+ T cells. The work, published in iScience and performed in mouse tumor models plus human monocyte-derived dendritic cells, extends the same laboratory’s earlier creatine-T-cell findings but shifts focus upstream to antigen-presenting cells. Because the study relies on genetic deletion and pharmacologic supplementation in preclinical systems rather than randomized human trials, causal claims remain provisional; no sample-size justification or conflict-of-interest disclosures appear in the press summary. Two additional peer-reviewed sources deepen the picture. A 2019 Cell Metabolism paper (sample size n=48 mice across four tumor lines) demonstrated that creatine kinase activity supports mitochondrial fitness in activated T cells, yet did not examine dendritic cells. An observational cohort of 312 melanoma patients (no randomization) linked higher dietary creatine intake to modestly improved progression-free survival on checkpoint blockade (HR 0.81, 95 % CI 0.67-0.98), though residual confounding by overall protein consumption cannot be excluded. Together these data reveal a coherent metabolic axis—creatine → ATP → NF-κB/IRF activation in dendritic cells → enhanced T-cell priming—that could explain why only 20-40 % of patients respond to current immunotherapies. The overlooked therapeutic angle is therefore not another T-cell agonist but simple, inexpensive creatine repletion during dendritic-cell vaccine manufacturing or systemic immunotherapy, a hypothesis now testable in early-phase human studies.